Research aims to improve interstitial lung disease prognosis with new imaging agent
Researchers at the University of Exeter and clinical radiopharmaceutical company Serac Healthcare Ltd are researching a new molecular imaging marker...
Imaging
Phase II PREDICT-ILD Imaging Study Commences in Interstitial Lung Disease
LONDON, Sept. 10, 2024 /PRNewswire/ -- Serac Healthcare Limited ("Serac Healthcare" or "the Company"), a clinical radiopharmaceutical company developing innovative...
Invenio completes enrolment in AI-based lung cancer imaging trial
Coming as part of a collaboration with pharmaceutical giant Johnson & Johnson, the multi-centre trial aims to test Invenio’s NIO...
Focus on diagnostic imaging for respiratory conditions: panel discussion
Speaking at Hospital Healthcare Europe’s Clinical Excellence in Respiratory Care event, our panel of three respiratory experts considered the use...
Brainomix swings FDA clearance for its lung imaging AI software
The FDA clearance follows after a phase II tralokinumab clinical trial published in the American Journal of Respiratory and Critical...
Painting a better picture of health: From faster delivery times to more accurate diagnoses, AI-powered medical imaging is revolutionising the future of our global healthcare system
The “rise of the machines” has played a critical role in advancing medical research and improving accuracy of diagnostic precision...
